New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 20, 2012
08:11 EDTACADACADIA to get funding from Fast Forward, EMD Serono for MS program
ACADIA Pharmaceuticals announced that it will receive funding from Fast Forward, a not-for-profit organization established by the National Multiple Sclerosis Society, and EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany. This funding will support ACADIA research, to be conducted in collaboration with Dr. Rhonda Voskuhl of UCLA, directed at using AC-186, ACADIA’s proprietary and selective estrogen receptor-beta agonist, as a new approach to the treatment of multiple sclerosis. Fast Forward and EMD Serono will provide up to $545,000 to support preclinical studies with AC-186 designed to further evaluate pharmacokinetics and its therapeutic potential in preclinical models of MS. This funding will be provided by the parties’ Accelerating Commercial Development Fund, which is allocated to for-profit entities and is designed to accelerate the development of research discoveries into new or improved therapies for people with MS.
News For ACAD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ACAD

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use